These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
269 related articles for article (PubMed ID: 18782502)
1. Spotlight on teriflunomide. Tallantyre E; Evangelou N; Constantinescu CS Int MS J; 2008 Jun; 15(2):62-8. PubMed ID: 18782502 [TBL] [Abstract][Full Text] [Related]
2. Teriflunomide for the treatment of multiple sclerosis. Oh J; O'Connor PW Semin Neurol; 2013 Feb; 33(1):45-55. PubMed ID: 23709212 [TBL] [Abstract][Full Text] [Related]
3. [TERIFLUNOMIDE: A NEW ORAL IMMUNOMODULATING AGENT FOR MULTIPLE SCLEROSIS]. Bencsik K; Rózsa C; Vécsei L Ideggyogy Sz; 2015 Mar; 68(3-4):79-87. PubMed ID: 26434194 [TBL] [Abstract][Full Text] [Related]
4. Teriflunomide for the treatment of relapsing multiple sclerosis: a review of clinical data. Brunetti L; Wagner ML; Maroney M; Ryan M Ann Pharmacother; 2013 Sep; 47(9):1153-60. PubMed ID: 24259730 [TBL] [Abstract][Full Text] [Related]
5. [Teriflunomide (Aubagio). New treatment for multiple sclerosis]. Sabourin G Perspect Infirm; 2014; 11(3):56. PubMed ID: 24855766 [No Abstract] [Full Text] [Related]
6. Teriflunomide for the treatment of multiple sclerosis. Warnke C; Stüve O; Kieseier BC Clin Neurol Neurosurg; 2013 Dec; 115 Suppl 1():S90-4. PubMed ID: 24321165 [TBL] [Abstract][Full Text] [Related]
7. Teriflunomide for the treatment of relapsing-remitting multiple sclerosis. Miller AE Expert Rev Clin Immunol; 2015 Feb; 11(2):181-94. PubMed ID: 25511008 [TBL] [Abstract][Full Text] [Related]
8. Teriflunomide (Aubagio®) for the treatment of multiple sclerosis. Bar-Or A Exp Neurol; 2014 Dec; 262 Pt A():57-65. PubMed ID: 24925677 [TBL] [Abstract][Full Text] [Related]
9. Teriflunomide: a review of its use in relapsing multiple sclerosis. Garnock-Jones KP CNS Drugs; 2013 Dec; 27(12):1103-23. PubMed ID: 24198223 [TBL] [Abstract][Full Text] [Related]
10. Aclidinium bromide, tofacitinib citrate, and teriflunomide. Hussar DA; Hurrey NJ J Am Pharm Assoc (2003); 2013; 53(1):106-10. PubMed ID: 23636164 [No Abstract] [Full Text] [Related]
11. Teriflunomide: A Review in Relapsing-Remitting Multiple Sclerosis. Scott LJ Drugs; 2019 Jun; 79(8):875-886. PubMed ID: 31098896 [TBL] [Abstract][Full Text] [Related]
12. Switching for convenience from first-line injectable treatments to oral treatments in multiple sclerosis: Data from a retrospective cohort study. Buard G; Giovannelli J; Outteryck O; Hadhoum N; Lannoy J; Vermersch P; Zéphir H Mult Scler Relat Disord; 2019 Aug; 33():39-43. PubMed ID: 31152966 [No Abstract] [Full Text] [Related]
13. Teriflunomide and its mechanism of action in multiple sclerosis. Bar-Or A; Pachner A; Menguy-Vacheron F; Kaplan J; Wiendl H Drugs; 2014 Apr; 74(6):659-74. PubMed ID: 24740824 [TBL] [Abstract][Full Text] [Related]
14. Synthesis of novel therapeutic agents for the treatment of multiple sclerosis: a brief overview. Mulakayala N; Rao P; Iqbal J; Bandichhor R; Oruganti S Eur J Med Chem; 2013 Feb; 60():170-86. PubMed ID: 23291119 [TBL] [Abstract][Full Text] [Related]
15. Leflunomide and teriflunomide: altering the metabolism of pyrimidines for the treatment of autoimmune diseases. Fragoso YD; Brooks JB Expert Rev Clin Pharmacol; 2015 May; 8(3):315-20. PubMed ID: 25712857 [TBL] [Abstract][Full Text] [Related]